These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28333415)

  • 1. Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Gupta AA; Chi YY; Anderson JR; Lyden E; Weigel B; Arndt C; Meyer WH; Rosenberg A; Hawkins DS
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28333415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
    Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
    Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
    J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Gupta AA; Anderson JR; Pappo AS; Spunt SL; Dasgupta R; Indelicato DJ; Hawkins DS
    Cancer; 2012 Feb; 118(4):1130-7. PubMed ID: 21761400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
    Breneman JC; Lyden E; Pappo AS; Link MP; Anderson JR; Parham DM; Qualman SJ; Wharam MD; Donaldson SS; Maurer HM; Meyer WH; Baker KS; Paidas CN; Crist WM
    J Clin Oncol; 2003 Jan; 21(1):78-84. PubMed ID: 12506174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rosenberg AR; Anderson JR; Lyden E; Rodeberg DA; Wolden SL; Kao SC; Parham DM; Arndt C; Hawkins DS
    Eur J Cancer; 2014 Mar; 50(4):816-23. PubMed ID: 24361229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
    McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C
    Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and outcome of patients with localized intrathoracic and chest wall rhabdomyosarcoma: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).
    Fuchs J; Urla C; Sparber-Sauer M; Schuck A; Leuschner I; Klingebiel T; Blumenstock G; Seitz G; Koscielniak E
    J Cancer Res Clin Oncol; 2018 May; 144(5):925-934. PubMed ID: 29464349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Vasquez JC; Luo LY; Hiniker SM; Rhee DS; Dasgupta R; Chen S; Weigel BJ; Xue W; Venkatramani R; Arndt CA
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30293. PubMed ID: 36916768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
    Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM
    J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
    Pappo AS; Lyden E; Breneman J; Wiener E; Teot L; Meza J; Crist W; Vietti T
    J Clin Oncol; 2001 Jan; 19(1):213-9. PubMed ID: 11134215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
    Ferrari A; Chisholm JC; Jenney M; Minard-Colin V; Orbach D; Casanova M; Guillen G; Glosli H; van Rijn RR; Schoot RA; Cameron AL; Rogers T; Alaggio R; Ben-Arush M; Mandeville HC; Devalck C; Defachelles AS; Coppadoro B; Bisogno G; Merks JHM
    Lancet Child Adolesc Health; 2022 Aug; 6(8):545-554. PubMed ID: 35690071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of oncological outcomes of combination chemotherapy as a monotherapy for a select patient subset with non-metastatic non-alveolar bladder/prostate rhabdomyosarcoma.
    Abdelhalim A; Atwa AM; Helmy TE; Dawaba ME; Elashry R; Hafez AT
    J Pediatr Urol; 2021 Aug; 17(4):535.e1-535.e8. PubMed ID: 34092511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcome of patients suffering from perineal/perianal rhabdomyosarcoma: results from the CWS trials--retrospective clinical study.
    Fuchs J; Dantonello TM; Blumenstock G; Kosztyla D; Klingebiel T; Leuschner I; Schuck A; Niggli FK; Koscielniak E; Seitz G
    Ann Surg; 2014 Jun; 259(6):1166-72. PubMed ID: 24045440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
    Rodeberg D; Arndt C; Breneman J; Lyden E; Donaldson S; Paidas C; Andrassy R; Meyer W; Wiener E
    J Pediatr Surg; 2005 Jan; 40(1):256-62. PubMed ID: 15868594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.